NYSE:ADCT ADC Therapeutics - ADCT News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. $5.05 +0.33 (+6.99%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.64▼$5.0750-Day Range$2.87▼$5.2052-Week Range$2.69▼$17.89Volume346,779 shsAverage Volume691,223 shsMarket Capitalization$387.89 millionP/E RatioN/ADividend YieldN/APrice Target$11.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address ADCT Media Mentions By Week ADCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADCT News Sentiment▼0.000.70▲Average Medical News Sentiment ADCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADCT Articles This Week▼82▲ADCT Articles Average Week All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineADC Therapeutics SA (NYSE:ADCT) Receives Average Recommendation of "Moderate Buy" from Brokeragesmarketbeat.com - January 25 at 5:09 AMADC Therapeutics SA (NYSE:ADCT) Receives $11.50 Average Target Price from Analystsamericanbankingnews.com - January 28 at 1:44 AMMorgan Stanley Trims ADC Therapeutics (NYSE:ADCT) Target Price to $5.00americanbankingnews.com - January 27 at 5:50 AMADC Therapeutics SA (NYSE:ADCT) Given Average Rating of "Moderate Buy" by Brokeragesamericanbankingnews.com - January 25 at 5:14 AMMorgan Stanley Reaffirms Their Hold Rating on ADC Therapeutics (ADCT)markets.businessinsider.com - January 24 at 1:50 PMThe Latest Analyst Ratings for ADC Therapeuticsmsn.com - January 24 at 1:50 PMCan ADC Therapeutics Strike Gold With Lymphoma Drug Zynlonta?markets.businessinsider.com - January 18 at 8:22 AMWall Street Analysts Think ADC Therapeutics SA (ADCT) Could Surge 174.2%: Read This Before Placing a Betfinance.yahoo.com - January 16 at 1:37 PMADC Therapeutics Uptrend Continuesnasdaq.com - January 14 at 3:22 PMAstraZeneca And Daiichi Sankyo's Zauberkugel (Magic Bullet)seekingalpha.com - January 6 at 2:26 PMPharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeuticsfinanznachrichten.de - January 5 at 8:56 AMIntoCell enters development and license option agreement with ADC Therapeuticsmsn.com - January 5 at 8:56 AM4 Analysts Have This to Say About ADC Therapeuticsmsn.com - January 4 at 9:17 AMADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 4 at 9:17 AMADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officerfinance.yahoo.com - January 3 at 6:48 PMADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphomafinance.yahoo.com - December 21 at 10:15 AMADC Therapeutics Appoints Jose Carmona as Chief Financial Officerfinance.yahoo.com - December 19 at 12:08 PMFREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTSfinance.yahoo.com - December 12 at 1:03 PMADC Therapeutics: Running Through A Stretch Of Bad Luckseekingalpha.com - November 30 at 10:01 AMBiocytogen Enters into Antibody Agreement with ADC Therapeuticsnz.finance.yahoo.com - November 27 at 7:15 PMBenzinga's Top Ratings Upgrades, Downgrades For November 9, 2022msn.com - November 9 at 11:24 AMADC Therapeutics SA (ADCT) Q3 2022 Earnings Call Transcriptseekingalpha.com - November 9 at 1:10 AMADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meetingfinance.yahoo.com - November 3 at 11:09 AMIGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphomafinance.yahoo.com - November 2 at 7:43 PMADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officerfinance.yahoo.com - November 1 at 8:29 AMADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022finance.yahoo.com - October 31 at 10:18 AMDown 27.9% in 4 Weeks, Here's Why You Should You Buy the Dip in ADC Therapeutics SA (ADCT)finance.yahoo.com - October 12 at 1:39 PMDown 28.5% in 4 Weeks, Here's Why ADC Therapeutics SA (ADCT) Looks Ripe for a Turnaroundfinance.yahoo.com - October 11 at 12:37 PMADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)finance.yahoo.com - September 21 at 7:16 PMADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphomafinance.yahoo.com - September 16 at 8:59 AMBronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ADC Therapeutics SA (ADCT) Investigationbenzinga.com - September 15 at 5:55 PMINVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firmapnews.com - September 14 at 4:52 PMINVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firmapnews.com - September 14 at 4:52 PMINVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firmapnews.com - September 14 at 1:15 AMWhere ADC Therapeutics Stands With Analystsmsn.com - September 9 at 4:44 PMExpert Ratings for ADC Therapeuticsmarkets.businessinsider.com - September 9 at 4:44 PMADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conferencefinance.yahoo.com - September 6 at 10:11 AMADC Therapeutics SA (ADCT) Q2 2022 Earnings Call Transcriptfinance.yahoo.com - August 10 at 3:17 AMADC Therapeutics SA (ADCT) CEO Ameet Mallik on Q2 2022 Results - Earnings Call Transcriptseekingalpha.com - August 9 at 5:16 PMADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimatesfinance.yahoo.com - August 9 at 5:16 PMADC Therapeutics SA: ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updatesfinanznachrichten.de - August 9 at 8:58 AMADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updatesfinance.yahoo.com - August 9 at 8:58 AMEarnings Outlook For ADC Therapeuticsmsn.com - August 8 at 5:57 PMIntercept Pharmaceuticals (ICPT) Reports Q2 Loss, Beats Revenue Estimates (Revised)finance.yahoo.com - August 5 at 8:11 AMADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022finance.yahoo.com - August 2 at 7:53 AMEarnings Preview: Moderna (MRNA) Q2 Earnings Expected to Declinefinance.yahoo.com - July 27 at 2:27 PMADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumorsfinance.yahoo.com - July 27 at 9:26 AMADC Therapeutics SA (ADCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?finance.yahoo.com - July 26 at 1:25 PMCentene (CNC) Gears Up for Q2 Earnings: What Lies Ahead?finance.yahoo.com - July 25 at 5:22 PMADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphomafinance.yahoo.com - July 20 at 10:12 AMAnalyst Forecasts For ADC Therapeutics SA (NYSE:ADCT) Are Surging Higherfinance.yahoo.com - July 16 at 8:49 AM Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NYSE:ADCT) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.